Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)

Open access
Wen, Patrick Y., Yung, W.K. Alfred, Lamborn, Kathleen R., Norden, Andrew D., Cloughesy, Timothy F., Abrey, Lauren E., Fine, Howard A., Chang, Susan M., Robins, H. Ian, Fink, Karen, DeAngelis, Lisa M., Mehta, Minesh, Di Tomaso, Emmanuelle, Drappatz, Jan, Kesari, Santosh, Ligon, Keith L., Aldape, Ken, Jain, Rakesh K., Stiles, Charles D., Egorin, Merrill J., Prados, Michael D.·2009·Neuro-Oncology

Abstract

Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially contributing to their pathogenesis. The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas. Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas. The primary end point was 6-month progression-free survival (6M-PFS). Patients requiring enzyme-inducing antiepileptic drugs were ineligible. Patients received imatinib at a dose of 600 mg/day for the first 4-week cycle and then gradually increased to 800 mg/day for subsequent cycles, if there were no unacceptable toxicities. Plasma concentrations of imatinib and its active metabolite, CGP74588, were assessed. Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible. The study was closed prematurely due to slow accrual. Tissue was available only from a minority of patients, but in these specimens there was uniform distribution of PDGFR, the drug target. Imatinib was generally well tolerated. Of 19 patients evaluable for response, 10 progressed at the first scan, and 9 were stable. There were no complete or partial responses. Overall median PFS was 2 months (range, 0.7-34 months); 6M-PFS was 29.4%. For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%. For atypical and malignant meningiomas, median PFS was 2 months (range, 0.7-3.7 months); 6M-PFS was 0%. Cycle 1 trough concentrations of imatinib and CGP74588 were 2,129 +/- 1,600 ng/ml and 517 +/- 326 ng/ml, respectively. Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas. Trough plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous leukemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1215/15228517-2009-010

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 162

Metadata

Authors
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., Fine, H. A., Chang, S. M., Robins, H. I., Fink, K., DeAngelis, L. M., Mehta, M., Di Tomaso, E., Drappatz, J., Kesari, S., Ligon, K. L., Aldape, K., Jain, R. K., Stiles, C. D., Egorin, M. J., & Prados, M. D.
Venue
Neuro-Oncology
Published
2009-12-01
Volume
11
Issue
6
Pages
853-860
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2027675488
Cited by
162
References
3
FWCI
7.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). https://app.cochat.ai/papers/10.1215/15228517-2009-010
The paper
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., Fine, H. A., Chang, S. M., Robins, H. I., Fink, K., DeAngelis, L. M., Mehta, M., Di Tomaso, E., Drappatz, J., Kesari, S., Ligon, K. L., Aldape, K., Jain, R. K., Stiles, C. D., . . . Prados, M. D. (2009). Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. https://doi.org/10.1215/15228517-2009-010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.